4,4-二甲基戊酸乙酯 | 10228-99-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4,4-二甲基戊酸乙酯
• 英文名称: ethyl 4,4-dimethylpentanoate
• CAS: 10228-99-6
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: PUJGGPCGKBGBAD-UHFFFAOYSA-N

物化性质

• 沸点：
  164.4±8.0 °C(Predicted)
• 密度：
  0.876±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4-二甲基戊酸乙酯 在 正丁基锂 、 N-环己基异丙基胺 、 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以61%的产率得到ethyl 2-iodo-4,4-dimethylpentanoate
  参考文献：
  名称：

  膦催化的偶氮甲碱亚胺环化：依赖于丙二烯的 [3 + 2]、[3 + 3]、[4 + 3] 和 [3 + 2 + 3] 通路

  摘要：

  在本文中，我们描述了膦催化的 [3 + 2]、[3 + 3]、[4 + 3] 和 [3 + 2 + 3] 偶氮甲碱亚胺和烯丙酸盐的环化。这些过程标志着偶氮甲碱亚胺首次用于亲核膦催化，产生二氮稠合的杂环，包括四氢吡唑并吡唑啉酮、-哒嗪酮、-二氮杂环酮和-重氮酮。计算 [3 + 3] 环化中的两种不同反应模式，有五种不同的反应途径 - 其选择取决于烯丙酸酯的结构和化学性质。所有反应操作简单，在温和的反应条件下顺利进行，以中等至优异的产率提供范围广泛的含 1,2-二氮杂环。由膦和两分子乙基 2 形成的两性离子中间体，3-丁二烯酸酯在偶氮甲碱亚胺的环化中充当 1,5-偶极子，导致 [3 + 2 + 3] 四氢吡唑并重氮酮产物。将两个烯丙酸分子结合到八元环产物中代表了这类多功能分子在亲核膦催化中的新应用。该协议的显着特点--可以轻松获得各种含氮杂环和偶氮甲碱亚胺底物的简单制备--表明它可能在杂环合成

  DOI：

  10.1021/ja200231v
• 作为产物：
  描述：

  ethyl 4,4-dimethylpent-2-ynoate 在 palladium on activated charcoal 氢气 作用下， 生成 4,4-二甲基戊酸乙酯
  参考文献：
  名称：

  β-Silyl Effects on the Stabilities of Carbanions and Carbon-Centered Radicals Derived from Ethyl Thionacetates, Diethyl Malonates, and Ethyl Acetoacetates

  摘要：

  The effects of an alpha-Me(3)SiCH(2) group on the equilibrium acidities in DMSO of the acidic C-H bonds in esters, including ethyl thionacetate, diethyl malonate, and ethyl acetoacetate, were found to differ from that of an alpha-MeCH(2) group by less than 1 kcal/mol, pointing to little or no stabilizing effect of a beta-Me(3)Si group on carbanion stabilities. On the other hand, substitution of an alpha-Me(3)SiCH(2) group for one of the acidic hydrogen atoms in these esters to give Me(3)SiCH(2)CH(2)C(=S)OEt, Me(3)SiCH(2)CH(CO(2)Et)(2), and Me(3)SiCH(2)CH(CO(2)Et)COCH3 was found to decrease the homolytic bond dissociation energies (BDEs) of the remaining acidic C-H bonds by 7.1, 8.2, and 7.1 kcal/mol, respectively, relative to those of the parent esters and by 2.7, 4.5, and 4.4 kcal/mol, respectively, relative to the BDEs of the acidic C-H bonds in the corresponding MeCH(2)-substituted esters. The differences in BDEs observed between the Me(3)SiCH(2)- and the MeCH(2)-substituted ester derivatives are indicative of the presence of 3-5 kcal/mol C-H bond stabilizing effects of beta-Me(3)Si groups, relative to those of beta-Me groups, on the corresponding carbon radicals. The BDE value of the acidic C-H bond in Me3(C)CH(2)CH(2)C(=S)OEt was found to be 86.4 kcal/mol, which represents a 0.6 kcal/mol increase in BDE relative to that of the acidic C-H bond in MeCH(2)CH(2)C(=S)OEt. This result demonstrates the absence of a stabilizing effect of a beta-tert-butyl group on an open-chain carbon-centered radical. This is contrary to an apparent 6.4 kcal/mol C-H bond stabilizing effect of the beta-tert-butyl group in 9-neopentylfluorene, relative to that in fluorene, which is attributed to the relief of steric strain in forming the radical.

  DOI：

  10.1021/jo951506g

文献信息

• PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics LLC

  公开号：US20180194762A1

  公开（公告）日：2018-07-12

  Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  公开了吡唑并[3,4-b]吡啶和吡咯并[2,3-b]吡啶作为布鲁顿酪氨酸激酶（Btk）的抑制剂。还公开了包含这些化合物的药物组合物。描述了使用Btk抑制剂的方法，单独使用或与其他治疗剂联合使用，用于治疗自身免疫性疾病或状况、异体免疫性疾病或状况、癌症（包括淋巴瘤）和炎症性疾病或状况。
• 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS
  申请人：Allergan, Inc.

  公开号：US20130123215A1

  公开（公告）日：2013-05-16

  The present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

  本发明涉及新颖的2,5-二氧代咪唑啉-1-基-3-苯基脲衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途，作为N-甲酰肽受体类似物-1（FPRL-1）受体的调节剂。
• DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
  申请人：MEDSHINE DISCOVERY INC.

  公开号：US20170197986A1

  公开（公告）日：2017-07-13

  Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种二氢嘧啶并环衍生物作为HBV抑制剂，特别涉及一种如下式（I）所示的化合物或其药用可接受的盐。
• Cathepsin S inhibitors
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040180886A1

  公开（公告）日：2004-09-16

  This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them. 1

  这项发明涉及具有以下式（I）和（II）的肽类化合物，其作为半胱氨酸蛋白酶抑制剂的卡托普汀S活性。这些化合物是选择性、可逆的卡托普汀S抑制剂，因此在治疗自身免疫和其他疾病方面具有用途。该发明还涉及制备这些化合物的方法和包含它们的药物组合物。
• [EN] ARYLAMIDES AND METHODS OF USE THEREOF<br/>[FR] ARYLAMIDES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENZYME CORP

  公开号：WO2021113806A1

  公开（公告）日：2021-06-10

  The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

  本公开涉及杂环化合物，其药用盐以及药物制剂。本文还描述了这些化合物的组成以及在治疗由CFTR活性缺陷介导的疾病和病况的方法中的使用，特别是囊性纤维化。